These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 36357822)
1. Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis. Wang J; Huang Y; Zhao F; Chen J; He L; Liu Z; Pei Y; Wei Z; Li R; Ai P; Peng X J Neurooncol; 2022 Nov; 160(2):433-443. PubMed ID: 36357822 [TBL] [Abstract][Full Text] [Related]
2. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389 [TBL] [Abstract][Full Text] [Related]
3. Observation versus radiotherapy with or without temozolomide in postoperative WHO grade II high-risk low-grade glioma: a retrospective cohort study. Wang J; Yan L; Ai P; He Y; Guan H; Wei Z; He L; Mu X; Liu Y; Peng X Neurosurg Rev; 2021 Jun; 44(3):1447-1455. PubMed ID: 32529528 [TBL] [Abstract][Full Text] [Related]
4. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840 [TBL] [Abstract][Full Text] [Related]
5. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma. Gramatzki D; Kickingereder P; Hentschel B; Felsberg J; Herrlinger U; Schackert G; Tonn JC; Westphal M; Sabel M; Schlegel U; Wick W; Pietsch T; Reifenberger G; Loeffler M; Bendszus M; Weller M Neurology; 2017 Apr; 88(15):1422-1430. PubMed ID: 28298550 [TBL] [Abstract][Full Text] [Related]
6. Effect of long-term adjuvant temozolomide chemotherapy on primary glioblastoma patient survival. Huang B; Yu Z; Liang R BMC Neurol; 2021 Nov; 21(1):424. PubMed ID: 34724914 [TBL] [Abstract][Full Text] [Related]
7. Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea. Kim BS; Seol HJ; Nam DH; Park CK; Kim IH; Kim TM; Kim JH; Cho YH; Yoon SM; Chang JH; Kang SG; Kim EH; Suh CO; Jung TY; Lee KH; Kim CY; Kim IA; Hong CK; Yoo H; Kim JH; Kang SH; Kang MK; Kim EY; Kim SH; Chung DS; Hwang SC; Song JH; Cho SJ; Lee SI; Lee YS; Ahn KJ; Kim SH; Lim DH; Gwak HS; Lee SH; Hong YK Cancer Res Treat; 2017 Jan; 49(1):193-203. PubMed ID: 27384161 [TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of low-dose temozolomide maintenance therapy in elderly patients with glioblastoma: a retrospective cohort study. Tao Q; Zhu T; Ge X; Gong S; Guo J Ann Palliat Med; 2022 Nov; 11(11):3513-3519. PubMed ID: 36464967 [TBL] [Abstract][Full Text] [Related]
10. The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma. Park CK; Lee SH; Kim TM; Choi SH; Park SH; Heo DS; Kim IH; Jung HW J Neurooncol; 2013 Apr; 112(2):277-83. PubMed ID: 23377829 [TBL] [Abstract][Full Text] [Related]
11. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years. Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669 [TBL] [Abstract][Full Text] [Related]
12. Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study. Kim YH; Park CK; Cho WH; Kim IA; Moon S; Choe G; Park SH; Kim IH; Kim DG; Jung HW; Lee MM; Bae SH; Cha SH; Kim CY J Neurooncol; 2011 Jul; 103(3):503-12. PubMed ID: 20862518 [TBL] [Abstract][Full Text] [Related]
13. Super-early initiation of temozolomide prolongs the survival of glioblastoma patients without gross-total resection: a retrospective cohort study. Jiang H; Zeng W; Ren X; Cui Y; Li M; Yang K; Elbaroody M; Lin S J Neurooncol; 2019 Aug; 144(1):127-135. PubMed ID: 31175579 [TBL] [Abstract][Full Text] [Related]
14. Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. Blumenthal DT; Gorlia T; Gilbert MR; Kim MM; Burt Nabors L; Mason WP; Hegi ME; Zhang P; Golfinopoulos V; Perry JR; Hyun Nam D; Erridge SC; Corn BW; Mirimanoff RO; Brown PD; Baumert BG; Mehta MP; van den Bent MJ; Reardon DA; Weller M; Stupp R Neuro Oncol; 2017 Aug; 19(8):1119-1126. PubMed ID: 28371907 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the clinical efficacy of temozolomide (TMZ) versus nimustine (ACNU)-based chemotherapy in newly diagnosed glioblastoma. Wang Y; Chen X; Zhang Z; Li S; Chen B; Wu C; Wang L; Zhang X; Wang J; Chen L; Jiang T Neurosurg Rev; 2014 Jan; 37(1):73-8. PubMed ID: 23912878 [TBL] [Abstract][Full Text] [Related]
16. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme. Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509 [TBL] [Abstract][Full Text] [Related]
17. Feasibility and safety of extended adjuvant temozolomide beyond six cycles for patients with glioblastoma. Hsieh SY; Chan DT; Kam MK; Loong HH; Tsang WK; Poon DM; Ng SC; Poon WS Hong Kong Med J; 2017 Dec; 23(6):594-8. PubMed ID: 28798282 [TBL] [Abstract][Full Text] [Related]
18. Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis. Gutenberg A; Bock HC; Reifenberger G; Brück W; Giese A Acta Neurochir (Wien); 2013 Mar; 155(3):429-35. PubMed ID: 23254891 [TBL] [Abstract][Full Text] [Related]
19. Bone marrow response as a potential biomarker of outcomes in glioblastoma patients. Vaios EJ; Nahed BV; Muzikansky A; Fathi AT; Dietrich J J Neurosurg; 2017 Jul; 127(1):132-138. PubMed ID: 27739940 [TBL] [Abstract][Full Text] [Related]
20. Radiotherapy with and without temozolomide in elderly patients with glioblastoma. Niyazi M; Schwarz SB; Suchorska B; Belka C Strahlenther Onkol; 2012 Feb; 188(2):154-9. PubMed ID: 22231634 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]